Venarus 50 mg + 450 mg

Indications

Therapy for symptoms of venous-lymphatic insufficiency: pain, cramps in the lower limbs, a feeling of heaviness and fullness in the legs, "fatigue" of the legs. Therapy for manifestations of venous-lymphatic insufficiency: edema of the lower limbs, trophic changes in the skin and subcutaneous tissue, venous trophic ulcers. Symptomatic therapy for acute and chronic hemorrhoids.

Method of administration and doses

Orally. The duration of the treatment course may last several months (up to 12 months). In case of recurrence of symptoms, upon the doctor's recommendation, the treatment course may be repeated. The recommended dose for acute hemorrhoids is 6 tablets per day: 3 tablets in the morning and 3 tablets in the evening for 4 days, then 4 tablets per day: 2 tablets in the morning and 2 tablets in the evening for the following 3 days. The recommended dose for chronic hemorrhoids is 2 tablets per day with meals.

Section: Composition

1 film-coated tablet contains:
active substances: hesperidin 50 mg (calculated as 100% substance)
diosmin 450 mg (calculated as 100% substance)
excipients: MCC - 124 mg; sodium carboxymethyl starch (sodium starch glycolate) - 54 mg; gelatin - 62 mg; talc - 12 mg; magnesium stearate - 8 mg
film coating: hypromellose (hydroxypropyl methylcellulose) - 41.4 mg; macrogol 6000 (polyethylene glycol 6000) - 6.76 mg; sodium lauryl sulfate - 0.2 mg; magnesium stearate - 2.48 mg; titanium dioxide - 7.88 mg; iron oxide red - 0.6 mg; iron oxide yellow - 0.68 mg

Description of the dosage form

Film-coated tablets of orange-pink color, biconvex, elongated shape, with rounded ends, with a score line.
In a cross-section - a core from grayish-yellow to brownish-gray color.

Contraindications

Increased sensitivity to active components or excipients included in the preparation.
Not recommended during breastfeeding.
Use during pregnancy and breastfeeding
Animal experiments did not reveal teratogenic effects. To date, there have been no reports of any side effects when the drug is used by pregnant women.
Due to the lack of data regarding the excretion of the drug in breast milk, the use of the drug during breastfeeding is not recommended.
Reproductive toxicity studies did not show any effects on reproductive function in rats of both sexes.

Special instructions

Before starting to take the Venarus® medication, it is recommended to consult a doctor. In case of exacerbation of hemorrhoids, the prescription of Venarus® does not replace specific treatment for other anal disorders. The duration of treatment should not exceed the timeframes specified in the section "Method of application and doses." If symptoms do not disappear after the recommended course of therapy, a consultation with a proctologist should be sought, who will select further therapy.

In the presence of venous circulation disorders, the maximum effect of treatment is achieved by combining therapy with a healthy (balanced) lifestyle: it is advisable to avoid prolonged sun exposure, long periods of standing, and it is also recommended to reduce excess body weight. Walking and, in some cases, wearing special stockings, contribute to improved blood circulation.

Contact a doctor immediately if your condition worsens or if there is no improvement during treatment.

Effect on the ability to drive vehicles and operate machinery. No effect.

Section: Side Effects

The frequency of adverse reactions is presented as follows: very often (≥1/10 cases); often (≥1/100 and

Overdose

There are no reported cases of overdose.
Treatment: seek medical assistance immediately.

Interaction

Not noted.
It is important to inform the attending physician about all medications being taken.

Pharmacodynamics

Venarus® has angioprotective and venotonic effects. It reduces the distensibility of veins, increases their tone, and decreases venous stasis; it lowers permeability and fragility of capillaries and increases their resistance; it improves microcirculation and lymphatic drainage.
With systematic use, it reduces the severity of clinical manifestations of chronic venous insufficiency of both organic and functional nature. The optimal dose-effect ratio is observed with a daily intake of 1000 mg.

Pharmacokinetics

The main excretion of the drug occurs through the intestines. On average, about 14% of the administered amount of the drug is excreted through the kidneys. T1/2 is 11 hours. The drug Venarus® undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine.

Описание

Venarus is a pharmaceutical drug intended for the treatment of venous and lymphatic vessel diseases. The drug is available in the form of film-coated tablets, with dosages of 50 mg and 450 mg. It contains diosmin and hesperidin, which help strengthen the walls of blood vessels, facilitate the outflow of blood and lymph, reduce inflammatory processes, and alleviate pain symptoms. Venarus is prescribed for various venous diseases, including chronic venous insufficiency, varicose veins, thrombosis, and venous ulcers. The pharmaceutical drug is taken only as prescribed by a doctor, following the dosage and regimen indicated in the instructions.